Kurt May rising through ISCO's ranks
This article was originally published in Clinica
International Stem Cell Corporation has promoted Kurt May, who was appointed senior vice-president in June, to president and chief operating officer. ISCO has also appointed Dr Andrey Semechkin, its CEO, co-chairman of the board with the company's founder, Kenneth Aldrich. The Carlsbad, California company specialises in stem cell technology called parthenogenesis that is designed to reduce the risk of immune rejection.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.